Growth • Insulet
PODD
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
22,9%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
43,9%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
104,8%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
98%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
80,5%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
34,3%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!